← Back to patent-cliff list
99mTc-ZHER2:41071
Tier C — Watch / trade99mTc-ZHER2:41071
Tomsk National Research Medical Center Of The Russian Academy Of Sciences
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：HER2
Indications (approved)：Breast cancer
Regional status
US
-
EU
Phase II
2025-10-20
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of 99mTc-ZHER2:41071?
Approved indications include: Breast cancer.
When does the 99mTc-ZHER2:41071 patent expire?
No public expiry year is available for 99mTc-ZHER2:41071 yet; this page updates once verified.
How do I get a quote for 99mTc-ZHER2:41071 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30